Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2

Cancer Gene Therapy

Volumn 23, Issue 10, 2016, Pages 341-347

  Kim, H ^a   Danishmalik, S N ^a   Hwang, H ^a   Sin, J I ^a   Oh, J ^b   Cho, Y ^b   Lee, H ^b   Jeong, M ^b   Kim, S H ^a   Hong, H J ^a  

^a Kangwon National University   (South Korea)

^b Research Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLASMID DNA; TRASTUZUMAB; DNA; ERBB2 PROTEIN, HUMAN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CANCER TRANSPLANTATION; CELL PROLIFERATION; CHEMISTRY; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE THERAPY; HEK293 CELL LINE; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PLASMID;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL PROLIFERATION; DNA; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PLASMIDS; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84988442231     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2016.37     Document Type: Article

References (34)

1. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs 2015; 7: 9-14.
2. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10: 345-352.
3. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21: 309-318.
4. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 2001; 1: 719-732.
5. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
6. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
7. Barnes LM, Bentley CM, Dickson AJ. Stability of protein production from recombinant mammalian cells. Biotechnol Bioeng 2003; 81: 631-639.
8. Reiter M, Blüml G. Large-scale mammalian cell culture. Curr Opin Biotechnol 1994; 5: 175-179.
9. Trill JJ, Shatzman AR, Ganguly S. Production of monoclonal antibodies in COS and CHO cells. Curr Opin Biotechnol 1995; 6: 553-560.
10. Cotrim AP, Baum BJ. Gene therapy: some history, applications, problems, and prospects. Toxicol Pathol 2008; 36: 97-103.
11. Friedmann T. The Development of Human Gene Therapy. Cold Spring Harbor Laboratory Press: New York, USA, 1999.
12. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
13. Zhang C, Wang QT, Liu H, Zhang ZZ, Huang WL. Advancement and prospects of tumor gene therapy. Chin J Cancer 2011; 30: 182-188.
14. Jiang M, Shi W, Zhang Q, Wang X, Guo M, Cui Z et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res 2006; 12(Pt 1): 6179-6185.
15. Shedlock DJ, Silvestri G, Weiner DB. Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol 2009; 9: 717-728.
16. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9: 776-788.
17. Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, Ramanathan AA et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011; 5: e928.
18. Yan J, Yoon H, Kumar S, Ramanathan MP, Corbitt N, Kutzler M et al. Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensusbased envelope DNA vaccine. Mol Ther 2007; 15: 411-421.
19. Morrow MP, Yan J, Pankhong P, Shedlock DJ, Lewis MG, Talbott K et al. IL-28B/IFNlambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther 2010; 18: 1714-1723.
20. Lang Kuhs KA, Ginsberg AA, Yan J, Wiseman RW, Khan AS, Sardesai NY et al. Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. Mol Ther 2012; 20: 669-678.
21. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012; 4: 155ra138.
22. Hirao LA, Draghia-Akli R, Prigge JT, Yang M, Satishchandran A, Wu L et al. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis 2011; 203: 95-102.
23. Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009; 83: 4624-4630.
24. Weiner DB. DNA vaccines: crossing a line in the sand. Introduction to special issue. Vaccine 2008; 26: 5073-5074.
25. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15: 617-648.
26. Sugar IP, Neumann E. Stochastic model for electric field-induced membrane pores. Electroporation. Biophys Chem 1984; 19: 211-225.
27. Sugar IP, Förster W, Neumann E. Model of cell electrofusion. Membrane electroporation, pore coalescence and percolation. Biophys Chem 1987; 26: 321-335.
28. Wolf H, Rols MP, Boldt E, Neumann E, Teissié J. Control by pulse parameters of electric field-mediated gene transfer in mammalian cells. Biophys J 1994; 66(Pt 1): 524-531.
29. Muthumani K, Flingai S, Wise M, Tingey C, Ugen KE, Weiner DB. Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab. Hum Vaccin Immunother 2013; 9: 2253-2262.
30. Flingai S, Plummer EM, Patel A, Shresta S, Mendoza JM, Broderick KE et al. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Sci Rep 2015; 5: 12616.
31. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-4289.
32. Wang G, Qiu J, Wang R, Krause A, Boyer JL, Hackett NR et al. Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer. Cancer Gene Ther 2010; 17: 559-570.
33. Razi Soofiyani S, Baradaran B, Lotfipour F, Kazemi T, Mohammadnejad L. Gene therapy, early promises, subsequent problems, and recent breakthroughs. Adv Pharm Bull 2013; 3: 249-255.
34. Leyland-Jones B, Arnold A, Gelmon K, Verma S, Ayoub JP, Seidman A et al. Pharmacologic insights into the future of trastuzumab. Ann Oncol 2001; 12(Suppl 1): S43-S47.